Fair W R, Scher H I
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Surg Oncol Clin N Am. 1997 Oct;6(4):831-46.
This article reviews the current status of neoadjuvant hormonal therapy (NHT) in the treatment of clinically localized prostate cancer. Although significant increases in the organ confined rate and similar marked decreases in the positive margin rate are found in patients receiving NHT, to date no difference in disease free survival rate, as determined by PSA values, can be shown. However, there is a suggestion (P = 10 ng/ ml when treated with NHT compared with controls. Given the prolonged natural history of prostate cancer, longer follow-up will be required before the value of NHT can be established.
本文综述了新辅助激素治疗（NHT）在临床局限性前列腺癌治疗中的现状。尽管接受NHT的患者器官局限率显著提高，切缘阳性率也有类似的显著降低，但迄今为止，根据前列腺特异性抗原（PSA）值确定的无病生存率并无差异。然而，有迹象表明（P = 10 ng/ml），与对照组相比，接受NHT治疗的患者的血清PSA水平在治疗后显著降低。鉴于前列腺癌的自然病程较长，在确定NHT的价值之前，需要更长时间的随访。 （注：原文中“However, there is a suggestion (P = 10 ng/ ml when treated with NHT compared with controls.”这句话似乎不完整且逻辑不太清晰，翻译时尽量按照现有内容进行了翻译。）
